Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
|
31653147 |
2019 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Alteration of expression of the tumor suppressor gene BRCA-1 has been widely studied in breast and ovarian carcinoma.
|
30446260 |
2019 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
BRCA1/2 pathogenic (P) and likely pathogenic (LP) germline variants are frequent among patients with ovarian carcinoma.
|
30606148 |
2019 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Risk-reducing salpingo-oophorectomy (RRSO) is recommended for BRCA1/2 mutation carriers because of their increased risk of ovarian carcinoma.
|
29315498 |
2018 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma.
|
29855141 |
2018 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience.
|
29460478 |
2018 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
|
29233532 |
2018 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
|
30266954 |
2018 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
|
28882436 |
2017 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
With the recent introduction of Poly(ADP-ribose) polymerase inhibitors, a promising novel therapy has become available for ovarian carcinoma (OC) patients with inactivating BRCA1 or BRCA2 mutations in their tumor.
|
27767231 |
2017 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A high proportion of young women with invasive OC have mutations in BRCA1, and a smaller fraction have mutations in other known OC genes.
|
26718727 |
2016 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Eligible patients are premenopausal BRCA1/2 mutation carriers after completing childbearing without (a history of) ovarian carcinoma.
|
26286255 |
2015 |
Ovarian Carcinoma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma--an Indian study.
|
24385383 |
2014 |
Ovarian Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Reduced BRCA1 gene expression is common in the sporadic form of ovarian carcinoma.
|
23339184 |
2013 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This study shows that BRCA1 IHC is well correlated with molecular events in ovarian carcinoma.
|
23232854 |
2013 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The germline BRCA1 mutation rate in USC subjects of 2% is higher than expected in a nonfounder population, suggesting that USC is associated with hereditary breast and ovarian carcinoma in a small proportion of cases.
|
22811390 |
2013 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.
|
22193042 |
2012 |
Ovarian Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We found that high-grade serous ovarian carcinoma had significantly higher MIR182 (P=0.0003) and HMGA2 (P=0.04) expression, and significantly lower BRCA1 (P<0.0001) and FOXO3 (P<0.001) expression than normal controls.
|
22790015 |
2012 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This study suggests that BRCA1 protein is a prognostic marker in sporadic OC patients with minimal RD.
|
21368065 |
2011 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we show that the p53-related gene p73, encoding a proapoptotic protein that is linked to chemosensitivity in many settings, is upregulated through a novel epigenetic mechanism in both human and murine models of BRCA1-associated ovarian carcinoma.
|
20807817 |
2010 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Four carriers of pathogenic mutations in both BRCA1 and BRCA2 were identified among women who underwent genetic counseling for hereditary susceptibility to breast and ovarian carcinoma at three different Italian institutions.
|
20373018 |
2010 |
Ovarian Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Low BRCA1 expression in primary sporadic ovarian carcinoma is associated with prolonged survival.
|
19602291 |
2009 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.
|
19060844 |
2009 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We propagated a novel BRCA1-null human ovarian cancer cell line UWB1.289 from a tumor of papillary serous histology, the most common form of ovarian carcinoma.
|
17259345 |
2007 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The identification of germ-line mutations in 2 genes (BRCA1 and BRCA2) responsible for the majority of hereditary ovarian cancers has led an increasing number of women carriers of these mutations to undergo prophylactic oophorectomy (PO) to reduce their risk of subsequent ovarian carcinoma.
|
17001151 |
2006 |